Key Takeaways
- • Private equity healthcare dealmaking reached record global deal value in 2025, with an estimated $191 billion in transactions, surpassing the previous 2021 peak and representing a 45% increase in deal value year-over-year, according to Bain & Company research cited by the Private Equity Stakeholder Project.
- • The Private Equity Stakeholder Project tracked 1,029 private equity-backed healthcare deals in the United States during 2025, comprising 151 leveraged buyouts, 664 add-on acquisitions, and 214 growth investments across 420 platform companies and 708 investment firms.
- • Health IT (151 deals), dental care (149 deals), outpatient care (148 deals), and medtech (117 deals) emerged as the most active subsectors, with behavioral health capturing 56 deals, reflecting PE investors' focus on fragmented, consolidation-ready segments.
- • Despite a higher interest rate and tariff environment, North American deal volume remained essentially flat between 2024 and 2025, with U.S.-specific data showing private equity dealmaking remained steady and resilient compared to global resurgence trends.
- • Biopharma led global healthcare PE deal value in 2025 with $80 billion, representing a significant increase from $55 billion in 2024, demonstrating robust investor appetite for pharmaceutical services and life sciences investments.
Summary
Private equity healthcare dealmaking experienced a record-breaking year in 2025, marked by exceptional global growth despite macroeconomic headwinds. According to research from Bain & Company tracked by the Private Equity Stakeholder Project (PESP), global healthcare PE deal value reached an estimated $191 billion in 2025, surpassing the previous peak set in 2021 and reflecting a 45% year-over-year increase. This resurgence signals renewed institutional investor confidence in the healthcare sector as a stable, long-term investment thesis, even as elevated interest rates and tariff pressures persisted throughout the year.
In the United States specifically, PESP documented 1,029 private equity-backed healthcare transactions during 2025, representing a comprehensive baseline of PE activity across the healthcare economy. This total comprises three distinct deal categories: 151 leveraged buyouts, representing control acquisitions of standalone healthcare entities; 664 add-on acquisitions, reflecting continued platform-building and consolidation within PE-owned portfolios; and 214 growth investments, which include minority stakes and expansion financing. These transactions involved 420 distinct platform companies—the PE-owned operating entities serving as acquisition vehicles—and 708 investment firms, illustrating the highly distributed nature of healthcare PE activity across multiple fund sizes and strategies.
Subsector concentration remained pronounced, with five areas capturing the majority of PE deal flow. Health IT dominated with 151 tracked deals, followed closely by dental care (149 deals) and outpatient care (148 deals). Medtech and medical device companies accounted for 117 deals, while behavioral health represented 56 transactions. This clustering reflects PE investors' systematic preference for fragmented, independently owned healthcare service segments with limited scale and substantial consolidation upside. These subsectors typically feature lower regulatory barriers to acquisition compared to hospital systems and payer entities, enabling rapid add-on strategies and operational scaling.
Market dynamics in North America diverged from the global growth narrative, with deal volume remaining essentially flat between 2024 and 2025 in the region. This stability in U.S. deal count, despite record global values, suggests that larger individual transactions and average deal sizes drove the 2025 valuation records rather than increased deal frequency. Notably, PE dealmaking in healthcare remained resilient in the face of persistent macroeconomic challenges, including elevated interest rates and heightened tariff uncertainty, positioning private equity as a consistent source of growth capital and consolidation activity for fragmented healthcare service providers.
The biopharma subsector proved particularly robust, generating $80 billion in global PE deal value during 2025, a substantial increase from $55 billion in 2024. This 45% growth in biopharma PE investment reflects institutional capital's sustained confidence in pharmaceutical services, contract manufacturing, and specialized distribution businesses as defensible, recurring-revenue platforms with strong cash generation profiles.
In the United States specifically, PESP documented 1,029 private equity-backed healthcare transactions during 2025, representing a comprehensive baseline of PE activity across the healthcare economy. This total comprises three distinct deal categories: 151 leveraged buyouts, representing control acquisitions of standalone healthcare entities; 664 add-on acquisitions, reflecting continued platform-building and consolidation within PE-owned portfolios; and 214 growth investments, which include minority stakes and expansion financing. These transactions involved 420 distinct platform companies—the PE-owned operating entities serving as acquisition vehicles—and 708 investment firms, illustrating the highly distributed nature of healthcare PE activity across multiple fund sizes and strategies.
Subsector concentration remained pronounced, with five areas capturing the majority of PE deal flow. Health IT dominated with 151 tracked deals, followed closely by dental care (149 deals) and outpatient care (148 deals). Medtech and medical device companies accounted for 117 deals, while behavioral health represented 56 transactions. This clustering reflects PE investors' systematic preference for fragmented, independently owned healthcare service segments with limited scale and substantial consolidation upside. These subsectors typically feature lower regulatory barriers to acquisition compared to hospital systems and payer entities, enabling rapid add-on strategies and operational scaling.
Market dynamics in North America diverged from the global growth narrative, with deal volume remaining essentially flat between 2024 and 2025 in the region. This stability in U.S. deal count, despite record global values, suggests that larger individual transactions and average deal sizes drove the 2025 valuation records rather than increased deal frequency. Notably, PE dealmaking in healthcare remained resilient in the face of persistent macroeconomic challenges, including elevated interest rates and heightened tariff uncertainty, positioning private equity as a consistent source of growth capital and consolidation activity for fragmented healthcare service providers.
The biopharma subsector proved particularly robust, generating $80 billion in global PE deal value during 2025, a substantial increase from $55 billion in 2024. This 45% growth in biopharma PE investment reflects institutional capital's sustained confidence in pharmaceutical services, contract manufacturing, and specialized distribution businesses as defensible, recurring-revenue platforms with strong cash generation profiles.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.